Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin.

Autor:	Yada M; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan., Yamamoto S; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Honma Y; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Hirano H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Okita N; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Shoji H; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Iwasa S; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Takashima A; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Nagahara A; Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan., Kato K; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; kenkato@ncc.go.jp.; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2024 Mar-Apr; Vol. 38 (2), pp. 761-766.
DOI:	10.21873/invivo.13499
Abstrakt:	Background/aim: Definitive chemoradiotherapy with cisplatin (CDDP) plus 5-fluorouracil is the standard treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC); however, CDDP is unsuitable for patients with cardiac and/or renal dysfunction. Based on the results of the PRODIGE5/ACCORD17 trial, 5-fluorouracil and leucovorin with oxaliplatin plus radiotherapy (FOLFOX-RT) has been recognized as a treatment option. However, the efficacy and safety of FOLFOX-RT is still unclear in Japan. Patients and Methods: Medical records were reviewed for patients with LA-ESCC who received FOLFOX-RT between April 2019 and July 2021 at our institution. We evaluated complete response rate, progression-free survival (PFS), overall survival (OS), and adverse events. Results: Fifteen patients were analyzed and median age was 72.5 years (range=51-83 years). All patients completed three courses of FOLFOX and the planned radiotherapy. The complete response rate was 40.0%. With a median follow-up of 10.6 months, the 6-month PFS rate was 63.0% (95%CI=32.3-82.8%), and the 6-month OS rate was 85.7% (95%CI=53.9-96.2%). Common adverse events were esophagitis (80.0%), leukopenia (53.3%), fatigue (53.3%), and neutropenia (46.7%). Only one patient had grade 4 esophageal perforation. Conclusion: FOLFOX-RT for LA-ESCC was well tolerated and could be a treatment option for CDDP-intolerant patients. (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu